share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

极光大麻 | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/08/07 04:16

Moomoo AI 已提取核心信息

Aurora Cannabis Inc. reported strong Q1 fiscal 2025 results with net revenue of $83.4M, up 12% YoY, and net income from continuing operations of $4.8M. Medical cannabis revenue grew 13% YoY to $47.2M, while plant propagation revenue increased 16% to $23.1M. The company achieved an adjusted EBITDA of $4.9M, up 87% YoY.The company maintained strong liquidity with $115.5M in cash and cash equivalents as of June 30, 2024. Adjusted gross margin before fair value adjustments on medical cannabis revenue improved to 69%, while operating cash flow turned positive at $8.4M compared to negative $11.2M in the prior year period.Post quarter, Aurora entered into a commercial collaboration agreement with Cogent International Manufacturing Ltd. for CBD lozenge distribution, expected to generate $9.8M in fixed fees over 24 months plus percentage-based revenue. The company continues to focus on profitable growth opportunities while maintaining its leading position in global medical cannabis markets.
Aurora Cannabis Inc. reported strong Q1 fiscal 2025 results with net revenue of $83.4M, up 12% YoY, and net income from continuing operations of $4.8M. Medical cannabis revenue grew 13% YoY to $47.2M, while plant propagation revenue increased 16% to $23.1M. The company achieved an adjusted EBITDA of $4.9M, up 87% YoY.The company maintained strong liquidity with $115.5M in cash and cash equivalents as of June 30, 2024. Adjusted gross margin before fair value adjustments on medical cannabis revenue improved to 69%, while operating cash flow turned positive at $8.4M compared to negative $11.2M in the prior year period.Post quarter, Aurora entered into a commercial collaboration agreement with Cogent International Manufacturing Ltd. for CBD lozenge distribution, expected to generate $9.8M in fixed fees over 24 months plus percentage-based revenue. The company continues to focus on profitable growth opportunities while maintaining its leading position in global medical cannabis markets.
Aurora大麻股公司报告了2025财年第一季度强劲的业绩,净营业收入为8340万,年增长12%,持续运营的净利润为480万。医疗大麻的营业收入同比增长13%,达到4720万,而植物繁殖的营业收入增长16%,达到2310万。该公司实现了490万的调整后息税折旧摊销前利润,年增长87%。截至2024年6月30日,该公司保持了强劲的流动性,现金及现金等价物为11550万。医疗大麻营业收入的调整后毛利率在公平价值调整之前提升至69%,而运营现金流转为正,达到840万,而去年同期为负1120万。季度后,Aurora与Cogent国际制造有限公司签署了一项商业合作协议,进行CBD含片的分销,预计在24个月内产生980万的固定费用外加基于百分比的收入。公司继续专注于有利可图的增长机会,同时保持其在全球医疗大麻市场的领先地位。
Aurora大麻股公司报告了2025财年第一季度强劲的业绩,净营业收入为8340万,年增长12%,持续运营的净利润为480万。医疗大麻的营业收入同比增长13%,达到4720万,而植物繁殖的营业收入增长16%,达到2310万。该公司实现了490万的调整后息税折旧摊销前利润,年增长87%。截至2024年6月30日,该公司保持了强劲的流动性,现金及现金等价物为11550万。医疗大麻营业收入的调整后毛利率在公平价值调整之前提升至69%,而运营现金流转为正,达到840万,而去年同期为负1120万。季度后,Aurora与Cogent国际制造有限公司签署了一项商业合作协议,进行CBD含片的分销,预计在24个月内产生980万的固定费用外加基于百分比的收入。公司继续专注于有利可图的增长机会,同时保持其在全球医疗大麻市场的领先地位。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息